Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Singapore Offers Public Funds To Bridge Valley Of Death, But Can It Last?  – BioMedical Asia

This article was originally published in PharmAsia News

Executive Summary

SINGAPORE - There is no dearth of research programs - the trouble is capital has evaporated and risk appetite is anorexic, BioMedical Asia speakers said in Singapore March 17

You may also be interested in...



Singapore, UK Award Infectious Disease Research Grants As Singapore Continues To Build Biomedical Research Base

SINGAPORE - Singapore and the United Kingdom have awarded SGD$4.5 million ($3.2 million) in grants covering six infectious disease research projects conducted jointly by Singapore and UK universities. The diseases include gastric flu, hepatitis B, dengue fever and tuberculosis

Singapore, UK Award Infectious Disease Research Grants As Singapore Continues To Build Biomedical Research Base

SINGAPORE - Singapore and the United Kingdom have awarded SGD$4.5 million ($3.2 million) in grants covering six infectious disease research projects conducted jointly by Singapore and UK universities. The diseases include gastric flu, hepatitis B, dengue fever and tuberculosis

PharmAsia News' Top Industry Trends Of 2009

As PharmAsia News wraps up its second year of publishing, we look back to some of the top trends and stories of 2009, as well as developing stories to keep an eye on in 2010

Related Content

UsernamePublicRestriction

Register

ID1131511

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel